tirzepatide india Waiting for a wonder drug?

This increasingly popular diabetes and weight loss medication has gained attention for its efficacy, but its also raising eyebrows with its potential side effects, including hair thinning

This is the second head-to-head study after Eli Lilly registered its intent to carry out a Phase 3b clinical trial in April 2023 that will see the companys tirzepatide (Mounjaro) compared with Novo Nordisks semaglutide (Wegovy) 2.4mg in 700 adult participants who have obesity or overweight with weight related comorbidities without Type 2 diabetes

This includes checking for problems like obstructive sleep apnea or gallbladder disease

Mounjaro is not currently approved for anyone under the age of 18